Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, 14059 Prague, Czech Republic.
Department of Urology, District Hospital Kladno, 27201 Kladno, Czech Republic.
Curr Oncol. 2021 Sep 3;28(5):3403-3407. doi: 10.3390/curroncol28050294.
Spontaneous regression of metastatic renal cell carcinoma (mRCC) is a rare event, often associated with an activation of innate immunity by various triggers. SARS-CoV-2 infection induces a strong inflammatory response in some patients and a cytokine storm is one of the main causes of severe morbidity and mortality associated with the virus. Here, we describe two cases of patients with histologically and radiologically proven mRCC whose treatment was delayed due to COVID-19 and who experienced spontaneous tumour regression following the infection. Both patients reported here had predominantly pulmonary and mediastinal involvement and underwent nephrectomy. The interval between the diagnosis of COVID-19 and the detection of tumour regression was 3 and 4 months, respectively. Although approved vaccines and other measures are clearly the best way to prevent COVID-19-associated morbidity and mortality in cancer patients, we hypothesize that innate immunity activation by the infection can contribute to tumour regression in special circumstances.
转移性肾细胞癌 (mRCC) 的自发消退是一种罕见的事件，通常与各种触发因素引起的固有免疫激活有关。SARS-CoV-2 感染可在某些患者中引发强烈的炎症反应，细胞因子风暴是与该病毒相关的严重发病率和死亡率的主要原因之一。在这里，我们描述了两例经组织学和影像学证实的 mRCC 患者，由于 COVID-19 其治疗被延迟，并且在感染后经历了自发的肿瘤消退。这里报告的两名患者主要有肺部和纵隔受累，并接受了肾切除术。从诊断 COVID-19 到发现肿瘤消退的间隔分别为 3 个月和 4 个月。尽管批准的疫苗和其他措施显然是预防癌症患者 COVID-19 相关发病率和死亡率的最佳方法，但我们假设感染引起的固有免疫激活可能有助于特殊情况下的肿瘤消退。
